期刊文献+

小剂量肝素治疗原发性胆汁性肝硬化重度黄疸的临床分析

原文传递
导出
摘要 目的探讨小剂量肝素治疗原发性胆汁性肝硬化(PBC)重度黄疸的临床价值。方法 62例患者随机分为对照组30例,应用熊去氧胆酸(UDCA)15mg/kg/d,口服。治疗组32例,给予5%葡萄糖200ml、低分子肝素50mg/d,静脉滴注。两组疗程均为4周。结果两组治疗结束后总胆红素(Tbil)分别为(197.42±83.91)和(89.34±47.29)3.28(P<0.05),两组总有效率为56.6%和81.2%(P<0.05)。结论小剂量肝素是治疗PBC重度黄疸的有效途径。
作者 范海清
出处 《医药论坛杂志》 2012年第3期114-114,116,共2页 Journal of Medical Forum
  • 相关文献

参考文献4

二级参考文献29

  • 1病毒性肝炎防治方案(试行)[J].中华传染病杂志,1995,13(4):241-247. 被引量:1767
  • 2江学良,张建忠,崔慧斐,董兆禄,王继尧.低分子肝素治疗急性黄疸型肝炎40例[J].新消化病学杂志,1997,5(5):296-296. 被引量:5
  • 3[1]Kowdley KV. Ursodeoxycholic acid therapy in the hepatobiliary disease. AmJ Med,2000,108(6) :481 - 6
  • 4[2]Poupon R, Chazouilleres O, Poupon RE. Chronic cholestatic diseases. J Hepatol, 2000,32(S1 ): 129 - 40
  • 5[3]Kumar D, Tandon RK. Use of ursodeoxycholic acid in liver diseases. J Gastroenterol Hepato1,2001,16( 1 ) :3 - 14
  • 6[4]Rodrigues CM,Fan G,Ma X,et al.A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest, 1998,101 (12) :2790 - 9
  • 7[5]Yerushalmi B, Dahl R, Devereaux MW, et al. Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition. Hepatology, 2001,33 (3): 616 - 26
  • 8[6]Keith BD. Ursodeoxycholic acid to inhibit the growth of hepatic metastases. Med Hypotheses,2000,55(5) :379 - 82
  • 9[7]Polzien F, Ramadori G. Increased intercellular adhesion molecule-I serum concentration in cholestasis. J Hepatol, 1996,25 (6): 877 - 86
  • 10[8]Bar Dayan D Y, Gershwin ME, Levi T, et al. Primary biliary cirrhosis. Is (and how much of) the pathology preventible? Immunol Res, 1998, 18 (2):117-23

共引文献14025

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部